Souhaitez-vous accéder aux communiqués récents ?

ACTG Presents Findings from REPRIEVE at CROI 2025 Presentations Address Frailty, Inflammation, Asymptomatic Heart Muscle Damage, and Mental Function

ACTG Presents Study at CROI Demonstrating Potential of CMV-specific Antiviral Inhibitor to Improve Aging-Related Outcomes among People Living with HIV

ACTG Presents Data from Mpox Study STOMP at CROI

Presentations highlight relationship between semaglutide and blood markers of gene modification age predictors, gut bacteria, heart and metabolic effects

ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen

ACTG Launches 2nd HIV Cure Clinical Trial in Africa Study Evaluating 2 Long-Acting Broadly Neutralizing Antibodies Given at HIV Treatment Initiation

Data demonstrate superiority of HepB-CpG vaccination over conventional hepatitis B vaccines among people living with HIV.

ACTG announced two oral presentations on tuberculosis (TB) therapy that took place at The Union Conference on Lung Health 2024, in Bali, Indonesia.

ACTG Presents Data Analysis at AIDS 2024 Showing Association between Elevated Risk of Cardiovascular Events and Abacavir Use Among People Living with HIV

PAUSE study in Africa is evaluating two long-acting broadly neutralizing antibodies